@article{JTD20044,
author = {Marcello Tiseo and Luca Boni and Andrea Ardizzoni},
title = {Is the door open to further investigation with antiangiogenesis in SCLC?},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 9},
year = {2018},
keywords = {},
abstract = {We thank Dr. Goto for his Editorial (1) on GOIRC-AIFA FARM6PMFJM study, the first randomized phase III trial evaluating the survival impact of bevacizumab combined to standard cisplatin-etoposide respect cisplatin-etoposide alone as first-line therapy of extended disease small cell lung cancer (SCLC) (2).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/20044}
}